Post-earnings recap
Reported
Thu, Aug 6, 2026
EPS actual
$0.28
EPS est.
$0.18
EPS surprise
+55.56%
1-day move
+6.19%
Aurinia Pharmaceuticals reported better-than-expected earnings per share, which contributed to a positive stock reaction, with shares rising by 6.19%. However, there was no revenue reported, which leaves some uncertainty about overall performance. Investors may be encouraged by the EPS beat, but the lack of revenue details and guidance could lead to cautious sentiment going forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.28 | $0.24 | +55.56% |
| Revenue | — | $80M | — |
No transcript is on record for the earnings call, so the analysis is based solely on numerical results.
Aurinia Pharmaceuticals Inc. is a biotechnology company focused on developing innovative therapies for kidney diseases. With a market cap of $2 billion, it plays a crucial role in the health care sector, particularly in addressing unmet medical needs in autoimmune and inflammatory conditions.
Last quarter
In Q1-2026, Aurinia reported an EPS of $0.25, significantly beating estimates of $0.18. However, the stock fell 6.80% the following day, indicating market skepticism despite the positive earnings surprise.
Management promises and guidance
EPS beat streak
4Q
EPS beat rate
75%
Avg EPS surprise
+144.50%
Avg 1-day reaction
+1.76%
Analysts expect Aurinia to continue its trend of beating earnings estimates, with a consensus EPS of $0.24 and revenue of $80 million. The market is watching closely for any signs of sustained growth.
Bull case
If Aurinia exceeds earnings expectations and provides positive guidance, it could signal strong demand for its products and lead to a significant stock rally.
Bear case
Conversely, if the company fails to meet expectations or provides weak guidance, it may raise concerns about its growth prospects and lead to a decline in stock price.
Key metrics to watch
EPS
$0.24Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$80MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Aurinia's revenue reach or exceed the $80 million consensus estimate?
Revenue performance will be critical in assessing the company's market traction and growth potential.
Q2
What guidance will management provide for future quarters?
Management's outlook will significantly influence investor sentiment and expectations for the company's growth trajectory.
—
Est. EPS
$0.67
Est. Rev
$396M
Impl. Move
±10.3%
Why consensus could be wrong
The Street may be underestimating the potential for Aurinia's new product pipeline to drive future growth, particularly in niche markets.
Supporting evidence
Aurinia has a history of beating earnings estimates, suggesting stronger operational performance than anticipated.
The company's recent investments in R&D could lead to breakthrough therapies that are not fully reflected in current forecasts.
Key risk
If revenue comes in below $78 million, it could undermine confidence in the company's growth strategy.
Pre-commit to what would confirm each case.
The market is debating Aurinia's ability to sustain growth in a competitive biotechnology landscape.
Bull confirmed if
An EPS of $0.29 or higher would confirm strong demand and operational efficiency.
Bear confirmed if
An EPS below $0.21 would raise concerns about the company's growth and profitability.
What the market is pricing for the move.
Implied Move
±23.81%
Historical Avg
±5.5%
The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±23.8% while AUPH has averaged ±5.5% over the last 8 prints — setup is pricing rich.
ATM IV
0.3%
30d HV
38.5%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Aurinia beats expectations, history suggests the stock could rise by about 1.03%, confirming strong demand and operational success.
In line / cautious
An in-line report may lead to muted reactions, as investors await further clarity on future guidance.
Miss
If the company misses expectations, the stock could drop by about 1.44%, raising concerns about its growth prospects.
The lines on the call that would change the story.